A copy of the Third Amendment is attached hereto as Exhibit 10.3, and is incorporated herein by reference. The foregoing description is qualified in its entirety by reference to the Third Amendment.
Item 2.03 | Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant. |
The information set forth under Item 1.01 of this Current Report on Form 8-K is incorporated herein by reference.
Item 5.02. | Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. |
Director Resignations
On February 13, 2023, Lee Wallace, Vanessa Douglas and Angelo Demasi, each a member of the Company’s Board of Directors (the “Board”), notified the Company that he/she was resigning from the Board effective as of immediately prior to funding of the loan under the New Credit Agreement. At the time of these resignations, Mr. Wallace served as a member of the Nominating and Corporate Governance Committee of the Board, Ms. Douglas served as a member of the Nominating and Corporate Governance Committee of the Board and Mr. Demasi served as a member of the Audit Committee of the Board and the Compensation Committee of the Board. None of Mr. Wallace’s, Ms. Douglas’s or Mr. Demasi’s resignations is the result of any disagreement with the Company relating to its operations, policies or practices or with the Board or management.
Appointment of New Directors
On February 13, 2023, the Board elected Timothy Bernlohr, Steven Scheiwe, Raphael Wallander and Lisa Gavales to the Board, effective as of the consummation of the transactions under the New Credit Agreement. The new directors will fill the vacancies on the Board created by the resignations of Mr. Wallace, Ms. Douglas, Mr. Demasi, and Richard Grellman, who resigned from the Board in December 2022.
Messrs. Bernlohr, Scheiwe and Wallander will each serve as a Class I director until the Company’s 2025 Annual Meeting of Stockholders and until his successor is duly elected and qualified, and Ms. Gavales will serve as a Class II Director until the Company’s 2023 Annual Meeting of Stockholders and until her successor is duly elected and qualified. The Board expects to appoint the new directors to the committees of the Board following the closing of the transactions contemplated by the Credit Agreement.
Each of Messrs. Bernlohr, Scheiwe and Wallander and Ms. Gavales will receive compensation for service as a non-employee director of the Company consistent with the compensation generally provided to other non-employee directors, as determined by the Board from time to time. Compensation for the Company’s non-employee directors is described in the Company’s definitive proxy statement filed with the Securities and Exchange Commission (“SEC”) on May 2, 2022.
Messrs. Bernlohr, Scheiwe and Wallander and Ms. Gavales have no direct or indirect material interest in any transaction required to be disclosed pursuant to Item 404(a) of Regulation S-K. The Board has determined each of Messrs. Bernlohr, Scheiwe and Wallander and Ms. Gavales is independent under SEC standards and the standards of the New York Stock Exchange.
On February 14, 2023, the Board elected Gene Davis, a current director, as Chairman of the Board. In addition, the Board appointed certain directors to the committees of the Board. The Company’s Compensation Committee membership consists of Timothy Bernlohr (Chair), Liz Josefsberg, Lisa Gavales, and Steven Scheiwe. The Company’s Audit Committee membership consists of Gene Davis (Chair), Timothy Bernlohr, Steven Scheiwe and Raphael Wallander. The Nominating and Corporate Governance Committee membership consists of Gene Davis (Chair), Lisa Gavales, Liz Josefsberg, and Michael Raymond.
Appointment of Interim CFO
On February 13, 2023, the Board appointed Robert Madore as Interim Chief Financial Officer, to serve while the Board conducts a formal search for a permanent Chief Financial Officer.
Mr. Madore, age 58, brings to the Company a proven track record of financial leadership spanning an impressive and diverse 30-year career. Mr. Madore most recently served as Chief Financial Officer of Cronos Group, a global cannabinoid company, from August 2021 to November 2022. Prior to joining Cronos Group, Mr. Madore served as Chief Financial Officer of MacAndrews & Forbes Incorporated, an operator of a diverse range of businesses, from January 2021 until March 2021. Prior to MacAndrews & Forbes Incorporated, Mr. Madore served as Executive